AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

AbbVie Inc.NYSE: ABBV

EBITDA · Q3 FY2026 · quarter ended Sep 2026

EBITDA grows, but more slowly than its trailing trend

Q3 FY2026 EBITDA of $6.48B rose 84.4% year over year, behind the +88.7% change in trailing-twelve-month EBITDA. Sequentially, it fell 24.7% from the prior quarter. Over 3 fiscal years it compounded at -10.0% a year.

Context

  • EBITDA amounted to 28.8% of revenue in FY2025, up 2.4 pp from a year earlier.
  • EBITDA increased in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 19 analysts of $39.01B (+121.3%) for the fiscal year ending Dec 2026, a step up from the +18.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
$6.48B-24.7% QoQ
Last fiscal yearDec 2025
$17.63B+18.2% YoY
LTMSep 2026
$24.15B+88.7% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+84.4%+100.7%+16.3 pp
1 year+18.2%+121.3%+103.0 pp
3-year CAGR-10.0%+37.3%+47.3 pp
5-year CAGR+23.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
17.63B USD
Year-over-year change
+18.2%
4-year CAGR
-7.4%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +88.7% is the 2nd highest of 10, against a peer median of +2.2%.
  • EBITDA amounts to 36.6% of revenue for ABBV, versus a peer median of 34.2%.
ABBV Competitors
EBITDA for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$43.3B USD+103.7%+54.1%54.4%
JNJJohnson & JohnsonLTM Sep 2026$30.81B USD-22.1%+15.6%31.0%
ABBVAbbVie Inc.LTM Sep 2026$24.15B USD+88.7%-10.0%36.6%
NVSNovartis AGLTM Jun 2026$22.26B USD-2.0%+16.1%40.0%
AZNAstraZeneca PLCLTM Sep 2026$21.37B USD+18.6%+29.7%34.4%
AMGNAmgen Inc.LTM Jun 2026$17.62B USD+10.8%+11.6%46.2%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$16.82B USD+11.6%-7.5%34.2%
MRKMerck & Co., Inc.LTM Jun 2026$13.93B USD-44.4%+9.9%21.0%
PFEPfizer Inc.LTM Jun 2026$13.49B USD-33.1%-25.8%21.2%
GSKGSK plcLTM Jun 2026£8.8B GBP+2.2%+6.5%26.5%
Peer median (excluding ABBV) —+2.2%+11.6%34.2%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.2B58.05B54.32B56.33B61.16B
Cost of Revenue17.45B17.41B20.42B16.9B18.2B
Gross Profit38.75B40.64B33.9B39.43B42.96B
Gross Margin69.0%70.0%62.4%70.0%70.2%
Research & Development8.05B6.51B7.68B12.79B9.1B
Selling, General & Admin12.35B15.26B12.87B14.75B14.01B
Operating Expenses20.83B22.52B21.15B30.29B22.87B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
EBITDA23.93B24.17B17.17B14.91B17.63B
EBITDA Margin42.6%41.6%31.6%26.5%28.8%
Operating Income17.92B18.12B12.76B9.14B20.09B
Operating Margin31.9%31.2%23.5%16.2%32.8%
Interest Income39M186M540M648M266M
Interest Expense2.42B2.23B2.22B2.81B2.89B
Other Income / Expenses(4.94B)(4.64B)(6.51B)(5.42B)(13.49B)
Income Before Tax12.99B13.48B6.25B3.72B6.6B
Pre-Tax Margin23.1%23.2%11.5%6.6%10.8%
Income Tax Expense1.44B1.63B1.38B(570M)2.36B
Net Income11.54B11.84B4.86B4.28B4.23B
Net Margin20.5%20.4%9.0%7.6%6.9%
EPS (Basic)6.486.652.732.402.37
EPS (Diluted)6.456.632.722.392.37
Weighted Avg Shares1.77B1.77B1.77B1.77B1.77B
Weighted Avg Shares (Diluted)1.78B1.78B1.77B1.77B1.77B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.